Deflazacort
Emflaza (deflazacort) is a small molecule pharmaceutical. Deflazacort was first approved as Emflaza on 2017-02-09. It is used to treat duchenne muscular dystrophy and inflammation in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Emflaza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emflaza | New Drug Application | 2021-02-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| duchenne muscular dystrophy | EFO_0000429 | D020388 | — |
| inflammation | MP_0001845 | D007249 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEFLAZACORT, EMFLAZA, PTC THERAP | |||
| 2026-06-07 | ODE-252 | ||
| 2024-02-09 | ODE-130 | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
228 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 7 | 15 | 7 | 17 | 46 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | 3 | 11 | 12 | 16 | 41 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 1 | 2 | 7 | 7 | 8 | 24 |
| Neoplasms | D009369 | C80 | 1 | 5 | 5 | 2 | 6 | 18 | |
| Thrombosis | D013927 | — | 2 | 2 | 4 | 6 | 14 | ||
| Thromboembolism | D013923 | HP_0001907 | — | 2 | 6 | 4 | 3 | 14 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | 2 | 1 | 9 | 13 | |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | 2 | 3 | 7 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 3 | 2 | 2 | — | 6 |
| Lung neoplasms | D008175 | C34.90 | 1 | 1 | 4 | 1 | — | 6 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | 1 | 3 | — | — | 4 | ||
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 2 | 3 |
| Lymphoma | D008223 | C85.9 | — | 1 | 1 | — | 1 | 3 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | — | 1 | 3 |
| Proliferative vitreoretinopathy | D018630 | EFO_1001129 | — | — | 3 | — | — | 3 | |
| Critical illness | D016638 | — | — | 2 | — | 1 | 3 | ||
| Diabetic foot | D017719 | EFO_1001459 | — | 3 | 3 | — | — | 3 | |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | 1 | 2 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | 1 | 2 |
| Thrombophilia | D019851 | D68.59 | — | — | 1 | — | 1 | 2 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | — | 2 | — | — | 2 | 4 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 2 | 3 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | — | 1 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Duodenal neoplasms | D004379 | — | 1 | — | — | — | 1 | ||
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | C24.9 | — | 1 | — | — | — | 1 | |
| Ampulla of vater cancer | — | — | 1 | — | — | — | 1 | ||
| Ischemic stroke | D000083242 | — | 1 | — | — | — | 1 | ||
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | 1 | — | — | — | 2 | 3 |
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Renal cell carcinoma | D002292 | 1 | — | — | — | — | 1 | ||
| Pseudotumor cerebri | D011559 | EFO_1001132 | G93.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | — | — | — | — | 2 | 2 | ||
| Embolism | D004617 | — | — | — | — | 1 | 1 | ||
| Cytokine release syndrome | D000080424 | D89.83 | — | — | — | — | 1 | 1 | |
| Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | 1 | 1 | ||
| Urolithiasis | D052878 | N20-N23 | — | — | — | — | 1 | 1 | |
| Gastrointestinal hemorrhage | D006471 | K92.2 | — | — | — | — | 1 | 1 | |
| Fertilization in vitro | D005307 | — | — | — | — | 1 | 1 | ||
| Assisted reproductive techniques | D027724 | — | — | — | — | 1 | 1 | ||
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEFLAZACORT |
| INN | deflazacort |
| Description | Deflazacort is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C |
Identifiers
| PDB | — |
| CAS-ID | 14484-47-0 |
| RxCUI | 22396 |
| ChEMBL ID | CHEMBL1201891 |
| ChEBI ID | — |
| PubChem CID | 189821 |
| DrugBank | DB11921 |
| UNII ID | KR5YZ6AE4B (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Emflaza - PTC Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,590 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,185 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more